A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Blood

• Publication date

  1995-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD.V86.3.906.BLOODJOURNAL863906PMID 7620184
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia.

  1994cited by this paper
• Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.

  1994cited by this paper
• Management of chronic myeloid leukemia in chronic phase with autologous stem cell transplantation and alpha-2 interferon: cytogenetic and clinical results.

  1993cited by this paper
• Chronic myelogenous leukemia: a concise update.

  1993cited by this paper
• Interferon alfa has become a standard in the treatment of chronic myelogenous leukemia.

  1993cited by this paper
• Effect of prior interferon alfa therapy on the outcome of allogeneic bone marrow transplantation for chronic myelogenous leukemia.

  1993cited by this paper
• Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group.

  1993cited by this paper
• Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.

  1993cited by this paper
• Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.

  1993cited by this paper
• Detection of minimal residual disease by polymerase chain reaction in Philadelphia chromosome-positive chronic myelogenous leukemia following interferon therapy.

  1992cited by this paper
• Polymerase chain reaction detection of residual disease in chronic myeloid leukemia patients in complete cytogenetic remission under interferon with or without chemotherapy.

  1992cited by this paper
• Molecular elimination of the minimal residual Ph1 clone with IFN alpha in CML.

  1992cited by this paper
• Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemia.

  1992cited by this paper
• Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gamma.

  1991cited by this paper
• A multicentre study of a randomized therapeutic protocol in previously untreated patients with Ph-positive chronic myelogenous leukaemia: interferon alfa-2b and hydroxyurea with or without cytosine arabinoside , preliminary results.

  1991cited by this paper
• Detection of residual leukemia after bone marrow transplant for chronic myeloid leukemia: role of polymerase chain reaction in predicting relapse.

  1991cited by this paper
• Recombinant human interferon (IFN) alpha‐2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti‐interferon antibodies

  1989cited by this paper
• Interferon alpha-2b as therapy for Ph'-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration.

  1988cited by this paper
• Cytostatic Therapy of Chronic Myelogenous Leukemia: Review and Perspectives

  1988cited by this paper
• Clinical investigation of human alpha interferon in chronic myelogenous leukemia.

  1987cited by this paper
• Bone marrow transplantation for patients with chronic myeloid leukemia.

  1986cited by this paper
• Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia.

  1986cited by this paper
• Analysis of survival by tumor response.

  1986cited by this paper
• Changes in granulocyte-monocyte colony-forming cells among leukocyte-interferon-treated chronic myelogenous leukemia patients.

  1986cited by this paper
• Prognostic discrimination in "good-risk" chronic granulocytic leukemia

  1984cited by this paper
• Prognostic discrimination in "good-risk" chronic granulocytic leukemia.

  1984cited by this paper
• Analysis of survival by tumor response.

  1983cited by this paper
• Results of treatment of Ph'+ chronic myelogenous leukemia with an intensive treatment regimen (L-5 protocol).

  1979cited by this paper
• [Clinical studies on the early diagnosis and treatment of blastic crisis of chronic myelogenous leukemia].

  1972cited by this paper

• Project Confirm: Accelerated Drug Approvals for Chronic Myeloid Leukemia.

  2022cites this paper
• Innate Immune Mechanisms and Immunotherapy of Myeloid Malignancies

  2021cites this paper
• Myeloid Leukemia Vaccines

  2018cites this paper
• Imatinib: Clinical Pharmacology and Therapeutic Results

  2017cites this paper
• Rôle de la signalisation calcique dans la leucémie myéloïde chronique

  2016cites this paper
• A Coiled-Coil Mimetic Intercepts BCR-ABL1 Dimerization in Native and Kinase-Mutant Chronic Myeloid Leukemia

  2015cites this paper
• The interferon-alpha revival in CML

  2015cites this paper
• Bone marrow transplantation improves autoinflammation and inflammatory bone loss in SH3BP2 knock-in cherubism mice.

  2015cites this paper
• Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: Importance of achieving treatment‐free remission

  2015cites this paper
• Treatment and Survival in Patients with Chronic Myeloid Leukemia in a Chronic Phase in West Iran.

  2015cites this paper
• Automated Synthesis and Visualization of a Chemotherapy Treatment Regimen Network

  2014cites this paper
• elastase diminished sensitivity to the antiproliferative effects of neutrophil Clonal dominance of chronic myelogenous leukemia is associated with

  2013cites this paper
• Chronic Phase of Chronic Myeloid Leukemia: Developed for the American Interferon, and Allogeneic Bone Marrow Transplantation in Treating the An Evidence-Based Analysis of the Effect of Busulfan, Hydroxyurea,

  2013cites this paper
• responders : a study of complete cytogenetic α Chronic myeloid leukemia and interferon-

  2013cites this paper
• A Guide to the Use of Interferon-Alpha in the Management of Chronic Myelogenous Leukaemia

  2012cites this paper
• Development of an Effective Therapy for CML

  2012cites this paper
• Possibility to Partly Win the War Against Cancer

  2012cites this paper
• Systematic review of comparative effectiveness data for oncology orphan drugs.

  2012cites this paper
• Evolution of clinical trial endpoints in chronic myeloid leukemia: efficacious therapies require sensitive monitoring techniques.

  2012cites this paper
• Re-emergence of interferon-α in the treatment of chronic myeloid leukemia

  2012cites this paper
• Interferon alpha for treatment of chronic myeloid leukemia.

  2011cites this paper
• Development of an Effective Therapy for Chronic Myelogenous Leukemia

  2011cites this paper
• Interferon alfa versus interferon alfa plus cytarabine combination therapy for chronic myeloid leukemia: a meta-analysis of randomized controlled trials.

  2011cites this paper
• Interferon: Current Status and Future Prospects in Cancer Therapy

  2011cites this paper
• Cancer immunotherapy.

  2011cites this paper
• Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.

  2011cites this paper
• Chronic myeloid leukemia: a historical perspective.

  2010cites this paper
• BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.

  2010cites this paper
• Cooperative oncology groups in Japan: Experience from the Japan Adult Leukemia Study Group

  2009cites this paper
• Myeloid Leukemia, Myelodysplasia, and Myeloproliferative Disease in Children

  2009cites this paper
• Role of the Immune System in Cancer Development and Therapeutic Implications

  2009cites this paper
• Interferons: therapy for cancer

  2009cites this paper
• Chronische myeloische Leukämie

  2009cites this paper
• [Immunological evaluation for CML and its possibility for an immunotherapy].

  2009cites this paper
• Interferon in chronic myeloid leukaemia: past and future.

  2009cites this paper
• Towards cure of CML: why we need to know more about CML stem cells?

  2009cites this paper
• Epidemiology of chronic myeloid leukaemia (CML).

  2009cites this paper
• [Limitations in application of imatinib in hematologic malignancies: are there new principal solutions?].

  2008cites this paper
• Cytokine-Based Therapy for Cancer

  2008cites this paper
• The role of interferon-alpha in the treatment of chronic myeloid leukemia.

  2007cites this paper
• The biology of chronic myelogenous leukemia: implications for imatinib therapy.

  2007cites this paper
• Clinical and Experimental Studies in Chronic Myeloid Leukemia : Studies of Treatment Outcome, In Vitro Cellular Drug Resistance and Gene Expression

  2007cites this paper
• Clinical Features of CML

  2007cites this paper
• Molecular Monitoring of Chronic Myeloid Leukemia Treated with Imatinib Mesylate

  2007cites this paper
• Treatment of chronic myeloid leukemia in the imatinib era

  2007cites this paper
• Wirkungsweisen der antineoplastischen Chemo- und Immuntherapie

  2007cites this paper
• Treatment of chronic myeloid leukemia with imatinib mesylate

  2006cites this paper
• Chronic myelogenous leukaemia (CML): an update.

  2006cites this paper
• Treatment of systemic mastocytosis.

  2006cites this paper
• Development of NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor

  2006cites this paper
• Development of a predictive population survival model according to the cytogenetic response rate for patients with chronic myeloid leukemia in the chronic phase

  2006cites this paper
• New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.

  2006cites this paper
• Leucémie myéloïde chronique

  2006cites this paper
• Systemic mastocytosis.

  2006cites this paper
• Interferon alpha and T-cell responses in chronic myeloid leukemia.

  2005cites this paper
• Personalized medical treatment strategies for patients with chronic myeloid leukemia

  2005cites this paper
• Interferon a and T-cell responses in chronic myeloid leukemia

  2005cites this paper
• Safety and efficacy of an indigenous recombinant interferon-alpha-2b in patients with chronic myelogenous leukaemia: results of a multicentre trial from India.

  2005cites this paper
• Interferon therapy in chronic myelogenous leukemia.

  2004cites this paper
• Immunity to chronic myelogenous leukemia.

  2004cites this paper
• Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemia

  2004cites this paper
• Interferon-α-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia

  2004cites this paper
• Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study

  2004cites this paper
• Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia.

  2004cites this paper
• Multicenter Prospective Study of Interferon α versus Allogeneic Stem Cell Transplantation for Patients with New Diagnoses of Chronic Myelogenous Leukemia

  2004cites this paper
• THE ROLE OF SRC FAMILY TYROSINE KINASES IN BCR-ABL SIGNAL TRANSDUCTION AND CHRONIC MYELOGENOUS LEUKEMIA

  2004cites this paper
• Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups.

  2004cites this paper
• Long‐term survival estimates for imatinib versus interferon‐α plus low‐dose cytarabine for patients with newly diagnosed chronic‐phase chronic myeloid leukemia

  2004cites this paper
• Interferon-alpha-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia.

  2004cites this paper
• Natural history and staging of chronic myelogenous leukemia.

  2004cites this paper
• Efficacy and Safety of Imatinib Mesylate for Patients in the First Chronic Phase of Chronic Myeloid Leukemia: Results of a Japanese Phase II Clinical Study

  2004cites this paper
• Optimizing treatment of chronic myeloid leukemia: a rational approach.

  2004cites this paper
• Initial expression of interferon alpha receptor 2 (IFNAR2) on CD34‐positive cells and its down‐regulation correlate with clinical response to interferon therapy in chronic myelogenous leukemia

  2004cites this paper
• The cytogenetic response as a surrogate marker of survival.

  2003cites this paper
• A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).

  2003cites this paper
• Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapy.

  2003cites this paper
• Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.

  2003cites this paper
• Management decisions in chronic myeloid leukemia.

  2003cites this paper
• Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon α

  2003cites this paper
• Therapeutic strategies for chronic myeloid leukemia in the chronic (stable) phase.

  2003cites this paper
• Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha.

  2003cites this paper
• Clonal dominance of chronic myelogenous leukemia is associated with diminished sensitivity to the antiproliferative effects of neutrophil elastase.

  2003cites this paper
• Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.

  2003influential citation
• Treatment of CML using IFN-alpha: impact on quality of life.

  2003cites this paper
• [Allogenic bone marrow transplantation in acute leukemias and chronic myeloid leukemia].

  2003cites this paper
• Chronic myelogenous leukemia

  2003cites this paper
• Chronic myeloid leukemia: Pathophysiology, diagnostic parameters, and current treatment concepts

  2003cites this paper
• Interferon-alfa for chronic myeloid leukemia.

  2003cites this paper
• A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses

  2003cites this paper
• Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia – prospective long-term results from a randomized-controlled trial

  2003cites this paper
• Innovations in the Management of Leukemia: Role of Biologic Therapies

  2003cites this paper
• CHAPTER 53 – Cytokines and cancer

  2003cites this paper
• [Chronic myeloid leukemia--treatment].

  2002cites this paper
• Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon α-2b for the treatment of chronic myelogenous leukemia patients in chronic phase

  2002cites this paper
• Sti‐571 in Chronic Myelogenous Leukaemia

  2002cites this paper
• Allogeneic Bone Marrow Transplantation in Children With Chronic Myelogenous Leukemia

  2002cites this paper
• The IFNs have been found to produce a large array of molecular and cellular actions of potential relevance to their use in cancer

  2002cites this paper
• [Current pharmacotherapy of chronic myeloid leukemia].

  2002cites this paper
• Biología molecular y tratamiento de la leucemia mieloide crónicaI. Biología molecular de la LMCII. Importancia de establecer factores pronósticos en leucemia mieloide crónica en el tratamiento con interferón alfa

  2002cites this paper
• Imatinib mesylate--a new oral targeted therapy.

  2002cites this paper